BioMedizone Immunology Research Competition: Nidhi Veerendra and Neil Panchal

Nidhi Veerendra and Neil Panchal

BioMedizone’s Immunology Research Competition

Evolution of Immunology: Navigating a Sea of Change to Targeted Therapies

Introduction

From more conventional immunization techniques, vaccination has taken a dramatic turn in

the development of targeted therapies that constitute a new horizon for the prevention and cure of

diseases. Still, such new modalities have also brought major social, ethical, and scientific

questions (Andrews et al.). The revolution in immunology demands efficient and accessible

modes. Immunotherapy must be evaluated with appropriate targeting in the broader public health

contexts of its use (Varadé et al. 24). For the first time, targeted immunotherapy offers a big jump

forward over the traditional vaccination in the prevention of disease. However, great challenges

lie ahead if these innovations are to benefit humanity across the world (Salzman et al. 79).

Societal implications

Gene therapies hold tremendous promise because targeted immunotherapies are deeply

social. They reinvigorate treatments that are specific to the patient's distinct genetic blueprint and

thus render healthcare more effective and efficient (Kohn et al. 40). However, most worriedly,

these new therapies can be conceived of and presumably cause inequalities in terms of

accessibility (Andrews et al.). Some treatment strategies are very expensive at this point; other

techniques will also most likely stay out of reach for marginalized communities due to resource

disparity (Salzman et al. 9). Such targeted therapy may also divert resources and attention away

from more traditional vaccine programs, which tend to undermine herd immunity and permit the

resurgence of preventable diseases (Lopez and Banerji 7).

Ethical considerations

Scientific discoveries have revolutionized the field of immunology but have also introduced

significant ethical challenges (Varadé et al. 19). Currently, an essential ethical problem is

weighing innovation against access. As new targeted therapies represent the acme of ingenuity,

general applicability will eventually be decided by the economy (Kohn et al. 27). Other issues

are those related to privacy concerning genetic information and the potential for genetic

discrimination (Andrews et al.). For example, informed consent becomes more challenging as

patients must fully understand the risks and benefits of these new treatments, which are often

more complex and less well-known than traditional vaccines. (Riley et al. 16).

Scientific challenges

Scientific challenges in developing these immunotherapies stem from the intricate

understanding required in this evolving field: both the immune system and its functions, as well

as its interactions with various diseases. Tailoring treatments demands extensive research and

rigorous testing to ensure safety and efficacy across diverse populations (Varadé et al. 10).

Besides, the scale-up of the production of targeted therapies is far more difficult and more

resource-demanding in comparison to classical vaccine production (Salzman et al. 20).

Moreover, long-term side effects from such treatments are not clear and need continuous

follow-up and study (Lopez and Banerji 7).

Future Direction

Consequently, future studies are therefore required to focus on upscaling to a size that will

allow for the cost of the targeted immunotherapies to be reduced to an affordable level for all

(Salzman et al. 21). There also needs to be efforts to embed targeting technologies within the

traditional vaccination approaches to ensure a robust, integrated public health strategy (Riley et

al. 17). If done correctly, this approach will lead to significant long-term effects and varied

efficacy of these therapies across diverse populations (Kohn et al. 22).

Conclusion

All in all, public education on the benefits and risks concerning targeted immunotherapies is

indispensable in raising awareness among people for proper decision-making and instilling trust

in these new forms of treatment (Varadé et al. 12). The shift from traditional vaccination to

targeted immunotherapies is a milestone in the history of immunology, irrevocably changing how

diseases are going to be prevented and treated (Lopez and Banerji 8). Such paradigm shifts come

hand in hand with challenges at societal, ethical, and scientific levels, which are needed to

maneuver carefully. This therefore calls for emphasis on research accessibility and equity, public

education, and stakeholder collaboration so that these life advances reach people. Integrating

innovation and equity to effectively and inclusively shape a vision for the future of immunology.

Works Cited

Andrews, Lori B., et al. "Social, Legal, and Ethical Implications of Genetic Testing." Assessing

Genetic Risks - NCBI Bookshelf, 1994, www.ncbi.nlm.nih.gov/books/NBK236044.

Kohn, Donald B., et al. "Successes and Challenges in Clinical Gene Therapy." Gene Therapy,

vol. 30, no. 10-11, 2023, pp. 738-746, https://doi.org/10.1038/s41434-023-00390-5.

Accessed 27 Aug. 2024.

Lopez, Juanita S., and Udai Banerji. "Combine and Conquer: Challenges for Targeted Therapy

Combinations in Early Phase Trials." Nature Reviews. Clinical Oncology, vol. 14, no. 1,

2017, p. 57, https://doi.org/10.1038/nrclinonc.2016.96. Accessed 27 Aug. 2024.

Riley, Rachel S., et al. "Delivery Technologies for Cancer Immunotherapy." Nature Reviews.

Drug Discovery, vol. 18, no. 3, 2019, p. 175, https://doi.org/10.1038/s41573-018-0006-z.

Accessed 27 Aug. 2024.

Salzman, Rachel, et al. "Addressing the Value of Gene Therapy and Enhancing Patient Access to

Transformative Treatments." Molecular Therapy, vol. 26, no. 12, 2018, pp. 2717-2726,

https://doi.org/10.1016/j.ymthe.2018.10.017. Accessed 27 Aug. 2024.

Varadé, Jezabel, et al. "Human Immunology and Immunotherapy: Main Achievements and

Challenges." Cellular and Molecular Immunology, vol. 18, no. 4, 2021, pp. 805-828,

https://doi.org/10.1038/s41423-020-00530-6. Accessed 27 Aug. 2024.